Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
65 hedge funds and large institutions have $342M invested in Y-mAbs Therapeutics in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
36% more capital invested
Capital invested by funds: $251M → $342M (+$91.5M)
10% more funds holding
Funds holding: 59 → 65 (+6)
6.34% more ownership
Funds ownership: 32.09% → 38.43% (+6.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$21.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.47M |
| 4 |
BlackRock
New York
|
+$4.36M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.56M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.97M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$686K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$253K |
| 5 |
Citigroup
New York
|
-$134K |
YMAB Hedge Fund Activity: Q3 2019 in Review
65 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2019, worth a combined $342M — up 36% from $251M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new YMAB positions and 5 closed out — a net gain of 6 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $5.56M.
- 65 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2019, up from 59 in Q2 2019.
- Funds reported $342M of Y-mAbs Therapeutics stock for Q3 2019, up 36% quarter-over-quarter.
- 11 funds opened new Y-mAbs Therapeutics positions in Q3 2019 and 5 closed out, a net change of +6 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2019 was Perceptive Advisors, an estimated $21.8M added.
- The largest Y-mAbs Therapeutics seller in Q3 2019 was Millennium Management, an estimated $5.56M sold.
Based on aggregated 13F filings for Q3 2019.